Vaccine hopes and M&A action power European stocks and U.S. equity futures

Capped vials of the University of Oxford’s COVID-19 vaccine candidate, which has restarted trials after a pause last week.


Vincenzo Pinto/Agence France-Presse/Getty Images

European stocks marched higher on Monday, alongside U.S. equity futures, driven by vaccine hopes, mergers and acquisitions news.

The Stoxx Europe 600 index
SXXP,
+0.26%

rose 0.5% after ending last week nearly 1.7% higher, the best weekly return since the week ending August 7. The German DAX
DAX,
+0.29%

gained 0.6%, the French CAC 40
PX1,
+0.46%

rose 0.9% and the FTSE 100 index
UKX,
+0.16%

gained 0.3% as well.

Investors will hear from the Federal Reserve, the Bank of England and the Bank of Japan in the coming days in a busy week for central bank meetings.

Wall Street was also pointing to a stronger start, with Nasdaq-100 futures
NQ00,
+1.35%

surging 200 points, or 1.2%, while S&P 500 futures
ES00,
+1.24%

rallied 37.47 points, or 1.4%, and Dow Jones Industrial Average futures
YM00,
+1.07%

jumped 340 points, or 1.3%.

Those gains came on the heels of a losing week for Wall Street, with the Dow
DJIA,
+0.47%

dropping 1.7%, the S&P 500
SPX,
+0.05%

falling 2.5% and the Nasdaq
COMP,
-0.60%

dropping 4.1%, its worst weekly loss since the week ending March 20.

Renewed hopes over a coronavirus vaccine also helped improved sentiment at the beginning of the week.

Pfizer Inc.’s
PFE,
+1.17%

chief executive officer Albert Bourla said in an interview Sunday that the drug maker should know if its COVID-19 vaccine candidate will work by the end of October — and if approved, it could be distributed in the U.S. by the end of the year. Pfizer is partnering with German drug maker BioNTech
BNTX,
+6.42%

on the vaccine’s development.

Oxford University also announced Saturday it would resume a trial for the coronavirus candidate it’s developing with AstraZeneca
AZN,
-0.05%
.
The study was halted last week following a U.K. patient falling ill pending a review into the “unexplained illness.” Oxford University said it has been deemed safe to continue. Shares of AstraZeneca rose 0.5%.

U.S.-based Gilead Sciences Inc. GILD announced a $21 billion deal on Sunday to buy biotech Immunomedics Inc. IMMU, maker of a key breast-cancer drug.

Japanese technology conglomerate SoftBank Group Corp. announced a $40 billion deal late Sunday to sell U.K.-based microprocessor designer Arm Holdings to chipmaker Nvidia
NVDA,
-1.19%

for a mix of cash and stock.

The technology sector was also lifted by M&A, with shares of German software group SAP SE
SAP,
+0.44%

up 0.5% and chip equipment maker ASML Holding NV
ASML,
+0.62%

ASML,
+0.50%

up 0.7%.

And the race for TikTok is heating up. Software group Oracle Corp.
ORCL,
-0.57%

had been tipped to take over the video-sharing app’s U.S. after China’s ByteDance apparently rejected an offer from technology giant Microsoft Corp.
MSFT,
-0.65%

But in the latest twist, Chinese state media say ByteDance has turned down Oracle as well.

Elsewhere, Euronext NV
ENX,
-2.60%

said Monday that it has submitted a non-binding offer to acquire Borsa Italiana from London Stock Exchange Group PLC
LSE,
-0.13%
.
The pan-European exchange partnered with Italian lenders Cassa Depositi e Prestiti Equity and Intesa Sanpaolo SpA
ISP,
-0.34%

on the offer. Euronext shares slipped 0.2% and London Stock Exchange shares rose 0.5%.

Be the first to comment

Leave a Reply

Your email address will not be published.


*